Recent Activity

Loading...

AUPH

Aurinia Pharmaceuticals Inc. · NASDAQ

Performance

+1.18%

1W

+1.98%

1M

-33.8%

3M

-37.88%

6M

-42.71%

YTD

-53.98%

1Y

Profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Investment Analysis Report: AUPH

Overview:

AUPH is a biotechnology company operating in the Health Technology sector with a market capitalization of $846 million. The company has shown significant fluctuations in its financial performance over the past three years, as evidenced by its balance sheets, income statements, and cash flow statements.

...
See more ...

Technical Analysis of AUPH 2024-05-03

Overview:

In analyzing the technical indicators for AUPH over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.

Trend Analysis:

...
See more ...

Recent News & Updates